{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T17:29:09Z","timestamp":1791480549030,"version":"4.3.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,26]],"date-time":"2021-09-26T00:00:00Z","timestamp":1632614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,26]],"date-time":"2021-09-26T00:00:00Z","timestamp":1632614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"mittelman integrative oncology family fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Timely detection of chemotherapy-induced peripheral neuropathy (CIPN) is critical to effectively tailor chemotherapy dose levels and offer supportive care. The purpose of this secondary analysis was to determine the reliability and validity of the two Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE\u2122) numbness and tingling severity and interference items to screen for CIPN in patients receiving taxanes, platinums, or proteasome inhibitors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Participants (<jats:italic>N<\/jats:italic>\u2009=\u2009142) completed the two PRO-CTCAE items, a 0\u201310 numerical rating scale of worst CIPN pain intensity, and the Quality of Life Questionnaire\u2013CIPN20 (QLQ-CIPN20) prior to three clinical visits (T1, T2, T3) during neurotoxic chemotherapy. Participants completed the two PRO-CTCAE items again following the T3 clinical visit (T4). In addition, study staff administered the modified Total Neuropathy Score\u2013Clinical Version (TNSc\u00a9) at T3. We examined floor (i.e., no CIPN severity or interference) and ceiling effects, test\u2013retest reliability, concurrent validity, longitudinal validity, construct validity of the response categories, and sensitivity and specificity of the two PRO-CTCAE items.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>At T3, 29% of participants had PRO-CTCAE severity scores at the floor; 60.1% of participants reported interference item scores at the floor. Agreements between scores reported at T3 and T4 for PRO-CTCAE severity (<jats:italic>ICC<\/jats:italic>\u2009=\u20090.79) and interference (<jats:italic>ICC<\/jats:italic>\u2009=\u20090.73) were moderate to strong. The PRO-CTCAE severity and interference items correlated moderately-strongly with QLQ-CIPN20 sensory (Spearman\u2019s <jats:italic>\u03c1-range<\/jats:italic>\u2009=\u20090.53\u20130.72) and motor (Spearman\u2019s <jats:italic>\u03c1-range<\/jats:italic>\u2009=\u20090.50\u20130.58) subscale scores. The Cohen\u2019s <jats:italic>d<\/jats:italic> from T1 to T3 for the PRO-CTCAE items were small (severity: <jats:italic>d<\/jats:italic>\u2009=\u20090.32, interference: <jats:italic>d<\/jats:italic>\u2009=\u20090.40) and comparable to the effect sizes for change observed with the QLQ-CIPN20. The PRO-CTCAE severity (0\u20133) and interference (0\u20132) response categories distinguished respondents with significantly different levels of QLQ-CIPN20 sensory and motor subscale scores (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001 via Jonckheere-Terpstra tests). The sensitivity and specificity of the PRO-CTCAE severity item (cutoff\u2009&gt;\u20090) to detect probable sensory peripheral neuropathy were 95.83% and 65.22%, while the sensitivity and specificity of the PRO-CTCAE\u2122 interference item (cutoff\u2009&gt;\u20090) were 51.39% and 73.91%.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Preliminary evidence supports the reliability and validity of the PRO-CTCAE numbness and tingling items for CIPN screening, although there may be floor effects and limitations in the capacity of the PRO-CTCAE items to identify the full range of CIPN sensory and motor features beyond numbness and tingling.<\/jats:p>\n                <jats:p><jats:italic>Trial Registration<\/jats:italic> ClinicalTrials.Gov, NCT03514680. Registered 21 April 2018. <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03514680\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03514680<\/jats:ext-link><\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s41687-021-00377-z","type":"journal-article","created":{"date-parts":[[2021,9,26]],"date-time":"2021-09-26T21:04:34Z","timestamp":1632690274000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Measurement properties of brief neuropathy screening items in cancer patients receiving taxanes, platinums, or proteasome inhibitors"],"prefix":"10.1186","volume":"5","clinical-trial-number":[{"clinical-trial-number":"nct03514680","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6996-5068","authenticated-orcid":false,"given":"Robert","family":"Knoerl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Mazzola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra A.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangxin","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elahe","family":"Salehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"McCleary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Ligibel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlen","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna L.","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,26]]},"reference":[{"key":"377_CR1","doi-asserted-by":"publisher","unstructured":"Nyrop KA, Deal AM, Reeder\u2010Hayes KE et al (2019) Patient\u2010reported and clinician\u2010reported chemotherapy\u2010induced peripheral neuropathy in patients with early breast cancer: current clinical practice. Cancer. https:\/\/doi.org\/10.1002\/cncr.32175","DOI":"10.1002\/cncr.32175"},{"key":"377_CR2","doi-asserted-by":"publisher","unstructured":"Shah A, Hoffman EM, Mauermann ML et al (2018) Incidence and disease burden of chemotherapy-induced peripheral neuropathy in a population-based cohort. J Neurol Neurosurg Psychiatry. https:\/\/doi.org\/10.1136\/jnnp-2017-317215","DOI":"10.1136\/jnnp-2017-317215"},{"key":"377_CR3","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3389\/fphar.2017.00086","volume":"8","author":"N Kerckhove","year":"2017","unstructured":"Kerckhove N, Collin A, Cond\u00e9 S, Chaleteix C, Pezet D, Balayssac D (2017) Long-term effects, pathophysiological mechanisms, and risk factors of chemotherapy-induced peripheral neuropathies: a comprehensive literature review. Front Pharmacol 8:86. https:\/\/doi.org\/10.3389\/fphar.2017.00086","journal-title":"Front Pharmacol"},{"issue":"5","key":"377_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/ecc.12443","volume":"26","author":"MAL Tanay","year":"2017","unstructured":"Tanay MAL, Armes J, Ream E (2017) The experience of chemotherapy-induced peripheral neuropathy in adult cancer patients: a qualitative thematic synthesis. Eur J Cancer Care (Engl) 26(5):e12443. https:\/\/doi.org\/10.1111\/ecc.12443","journal-title":"Eur J Cancer Care (Engl)"},{"key":"377_CR5","doi-asserted-by":"publisher","unstructured":"Tanay MA, Armes J (2019) Lived experiences and support needs of women who developed chemotherapy-induced peripheral neuropathy following treatment for breast and ovarian cancer. Eur J Cancer Care (Engl). https:\/\/doi.org\/10.1111\/ecc.13011","DOI":"10.1111\/ecc.13011"},{"issue":"23","key":"377_CR6","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1200\/JCO.2016.71.3552","volume":"35","author":"KM Winters-Stone","year":"2017","unstructured":"Winters-Stone KM, Horak F, Jacobs PG et al (2017) Falls, functioning, and disability among women with persistent symptoms of chemotherapy-induced peripheral neuropathy. J Clin Oncol 35(23):2604\u20132612. https:\/\/doi.org\/10.1200\/JCO.2016.71.3552","journal-title":"J Clin Oncol"},{"key":"377_CR7","doi-asserted-by":"publisher","unstructured":"Loprinzi CL, Lacchetti C, Bleeker J et al (2020) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.20.01399","DOI":"10.1200\/JCO.20.01399"},{"key":"377_CR8","doi-asserted-by":"publisher","unstructured":"McCrary JMM, Goldstein D, Boyle F et al (2017) Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey. https:\/\/doi.org\/10.1007\/s00520-017-3772-y","DOI":"10.1007\/s00520-017-3772-y"},{"issue":"3","key":"377_CR9","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","volume":"13","author":"A Trotti","year":"2003","unstructured":"Trotti A, Colevas A, Setser A et al (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13(3):176\u2013181. https:\/\/doi.org\/10.1016\/S1053-4296(03)00031-6","journal-title":"Semin Radiat Oncol"},{"issue":"10","key":"377_CR10","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1007\/s11136-013-0379-8","volume":"22","author":"EML Smith","year":"2013","unstructured":"Smith EML, Barton DL, Qin R, Steen PD, Aaronson NK, Loprinzi CL (2013) Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire. Qual Life Res 22(10):2787\u20132799. https:\/\/doi.org\/10.1007\/s11136-013-0379-8","journal-title":"Qual Life Res"},{"issue":"11","key":"377_CR11","doi-asserted-by":"publisher","first-page":"3437","DOI":"10.1007\/s00520-017-3764-y","volume":"25","author":"R Knoerl","year":"2017","unstructured":"Knoerl R, Gray E, Stricker C et al (2017) Electronic versus paper-pencil methods for assessing chemotherapy-induced peripheral neuropathy. Support Care Cancer 25(11):3437\u20133446. https:\/\/doi.org\/10.1007\/s00520-017-3764-y","journal-title":"Support Care Cancer"},{"issue":"5","key":"377_CR12","doi-asserted-by":"publisher","first-page":"E134","DOI":"10.1188\/18.CJON.E134-E140","volume":"22","author":"R Knoerl","year":"2018","unstructured":"Knoerl R, Bridges C, Smith G, Yang J, Kanzawa-Lee G, Smith E (2018) Chemotherapy-induced peripheral neuropathy: use of an electronic care planning system to improve adherence to recommended assessment and management practices. Clin J Oncol Nurs 22(5):E134\u2013E140. https:\/\/doi.org\/10.1188\/18.CJON.E134-E140","journal-title":"Clin J Oncol Nurs"},{"issue":"4","key":"377_CR13","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/j.1529-8027.2010.00292.x","volume":"15","author":"KA Griffith","year":"2010","unstructured":"Griffith KA, Merkies IS, Hill EE, Cornblath DR (2010) Measures of chemotherapy-induced peripheral neuropathy: a systematic review of psychometric properties. J Peripher Nerv Syst 15(4):314\u2013325. https:\/\/doi.org\/10.1111\/j.1529-8027.2010.00292.x","journal-title":"J Peripher Nerv Syst"},{"issue":"3","key":"377_CR14","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.ejca.2009.12.008","volume":"46","author":"G Cavaletti","year":"2010","unstructured":"Cavaletti G, Frigeni B, Lanzani F et al (2010) Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer 46(3):479\u2013494. https:\/\/doi.org\/10.1016\/j.ejca.2009.12.008","journal-title":"Eur J Cancer"},{"issue":"9","key":"377_CR15","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/j.pec.2019.04.012","volume":"102","author":"R Knoerl","year":"2019","unstructured":"Knoerl R, Smith EML, Han A, Doe A, Scott K, Berry DL (2019) Characterizing patient-clinician chemotherapy-induced peripheral neuropathy assessment and management communication approaches. Patient Educ Couns 102(9):1636\u20131643. https:\/\/doi.org\/10.1016\/j.pec.2019.04.012","journal-title":"Patient Educ Couns"},{"key":"377_CR16","unstructured":"National Cancer Institute (2021) Patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAETM). https:\/\/healthcaredelivery.cancer.gov\/pro-ctcae\/"},{"key":"377_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju244","author":"E Basch","year":"2014","unstructured":"Basch E, Reeve BB, Mitchell SA et al (2014) Development of the National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/dju244","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"377_CR18","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1001\/jamaoncol.2015.2639","volume":"1","author":"AC Dueck","year":"2015","unstructured":"Dueck AC, Mendoza TR, Mitchell SA et al (2015) Validity and reliability of the US National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). JAMA Oncol 1(8):1051\u20131059. https:\/\/doi.org\/10.1001\/jamaoncol.2015.2639","journal-title":"JAMA Oncol"},{"issue":"1","key":"377_CR19","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s11136-013-0470-1","volume":"23","author":"JL Hay","year":"2014","unstructured":"Hay JL, Atkinson TM, Reeve BB et al (2014) Cognitive interviewing of the US National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Qual Life Res 23(1):257\u2013269. https:\/\/doi.org\/10.1007\/s11136-013-0470-1","journal-title":"Qual Life Res"},{"key":"377_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-019-04781-6","author":"AC Tan","year":"2019","unstructured":"Tan AC, McCrary JM, Park SB, Trinh T, Goldstein D (2019) Chemotherapy-induced peripheral neuropathy\u2014patient-reported outcomes compared with NCI-CTCAE grade. Support Care Cancer. https:\/\/doi.org\/10.1007\/s00520-019-04781-6","journal-title":"Support Care Cancer"},{"key":"377_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2019.07.021","author":"JM McCrary","year":"2019","unstructured":"McCrary JM, Goldstein D, Trinh T et al (2019) Optimising clinical screening for chemotherapy-induced peripheral neuropathy. J Pain Symptom Manag. https:\/\/doi.org\/10.1016\/j.jpainsymman.2019.07.021","journal-title":"J Pain Symptom Manag"},{"issue":"1","key":"377_CR22","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s12885-021-07965-8","volume":"21","author":"R Knoerl","year":"2021","unstructured":"Knoerl R, Mazzola E, Hong F et al (2021) Exploring the impact of a decision support algorithm to improve clinicians\u2019 chemotherapy-induced peripheral neuropathy assessment and management practices: a two-phase, longitudinal study. BMC Cancer 21(1):236. https:\/\/doi.org\/10.1186\/s12885-021-07965-8","journal-title":"BMC Cancer"},{"issue":"3","key":"377_CR23","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/ana.410350310","volume":"35","author":"V Chaudhry","year":"1994","unstructured":"Chaudhry V, Rowinsky EK, Sartorius SE, Donehower RC, Cornblath DR (1994) Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol 35(3):304\u2013311. https:\/\/doi.org\/10.1002\/ana.410350310","journal-title":"Ann Neurol"},{"issue":"8","key":"377_CR24","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1212\/WNL.53.8.1660","volume":"53","author":"DR Cornblath","year":"1999","unstructured":"Cornblath DR, Chaudhry V, Carter K et al (1999) Total neuropathy score: validation and reliability study. Neurology 53(8):1660\u20131664","journal-title":"Neurology"},{"key":"377_CR25","doi-asserted-by":"publisher","DOI":"10.1177\/1073274818756608","author":"EML Smith","year":"2018","unstructured":"Smith EML, Knoerl R, Yang JJ, Kanzawa-Lee G, Lee D, Bridges CM (2018) In search of a gold standard patient-reported outcome measure for use in chemotherapy-induced peripheral neuropathy clinical trials. Cancer Control. https:\/\/doi.org\/10.1177\/1073274818756608","journal-title":"Cancer Control"},{"issue":"2","key":"377_CR26","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1188\/11.ONF.133-142","volume":"38","author":"EM Lavoie Smith","year":"2011","unstructured":"Lavoie Smith EM, Cohen JA, Pett MA et al (2011) The validity of neuropathy and neuropathic pain measures in patients with cancer receiving taxanes and platinums. Oncol Nurs Forum 38(2):133\u2013142. https:\/\/doi.org\/10.1188\/11.ONF.133-142","journal-title":"Oncol Nurs Forum"},{"issue":"1","key":"377_CR27","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1188\/08.ONF.96-102","volume":"35","author":"EML Smith","year":"2008","unstructured":"Smith EML, Beck SL, Cohen J (2008) The total neuropathy score: a tool for measuring chemotherapy-induced peripheral neuropathy. Oncol Nurs Forum 35(1):96\u2013102. https:\/\/doi.org\/10.1188\/08.ONF.96-102","journal-title":"Oncol Nurs Forum"},{"issue":"3","key":"377_CR28","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/NCC.0b013e3181c989a3","volume":"33","author":"EML Smith","year":"2010","unstructured":"Smith EML, Cohen JA, Pett MA, Beck SL (2010) The reliability and validity of a modified total neuropathy score-reduced and neuropathic pain severity items when used to measure chemotherapy-induced peripheral neuropathy in patients receiving taxanes and platinums. Cancer Nurs 33(3):173\u2013183. https:\/\/doi.org\/10.1097\/NCC.0b013e3181c989a3","journal-title":"Cancer Nurs"},{"issue":"1\u20132","key":"377_CR29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.pain.2004.09.012","volume":"113","author":"RH Dworkin","year":"2005","unstructured":"Dworkin RH, Turk DC, Farrar JT et al (2005) Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 113(1\u20132):9\u201319. https:\/\/doi.org\/10.1016\/j.pain.2004.09.012","journal-title":"Pain"},{"issue":"2","key":"377_CR30","first-page":"129","volume":"23","author":"CS Cleeland","year":"1994","unstructured":"Cleeland CS, Ryan KM (1994) Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singap 23(2):129\u2013138","journal-title":"Ann Acad Med Singap"},{"issue":"8","key":"377_CR31","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.ejca.2005.02.012","volume":"41","author":"TJ Postma","year":"2005","unstructured":"Postma TJ, Aaronson NK, Heimans JJ et al (2005) The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 41(8):1135\u20131139","journal-title":"Eur J Cancer"},{"issue":"11","key":"377_CR32","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1007\/s00520-017-3780-y","volume":"25","author":"J Le-Rademacher","year":"2017","unstructured":"Le-Rademacher J, Kanwar R, Seisler D et al (2017) Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel\/carboplatin-induced peripheral neuropathy in NCCTG\/Alliance clinical trials. Support Care Cancer 25(11):3537\u20133544. https:\/\/doi.org\/10.1007\/s00520-017-3780-y","journal-title":"Support Care Cancer"},{"issue":"4","key":"377_CR33","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s11136-018-2076-0","volume":"28","author":"S Qin","year":"2019","unstructured":"Qin S, Nelson L, McLeod L, Eremenco S, Coons SJ (2019) Assessing test\u2013retest reliability of patient-reported outcome measures using intraclass correlation coefficients: recommendations for selecting and documenting the analytical formula. Qual Life Res 28(4):1029\u20131033. https:\/\/doi.org\/10.1007\/s11136-018-2076-0","journal-title":"Qual Life Res"},{"key":"377_CR34","unstructured":"Hinkle DE, Wiersma W, Jurs SG (2003). Applied statistics for the behavioral sciences, 5th edn. Houghton Mifflin. https:\/\/books.google.com\/books?id=7tntAAAAMAAJ"},{"key":"377_CR35","doi-asserted-by":"crossref","unstructured":"Liang MH (2000) Longitudinal construct validity: establishment of clinical meaning in patient evaluative instruments. Med Care 38(9 Suppl)","DOI":"10.1097\/00005650-200009002-00013"},{"issue":"6","key":"377_CR36","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1080\/03610910801894870","volume":"37","author":"R Ferdhiana","year":"2008","unstructured":"Ferdhiana R, Terpstra J, Magel RC (2008) A nonparametric test for the ordered alternative based on Kendall\u2019s correlation coefficient. Commun Stat Simul Comput 37(6):1117\u20131128. https:\/\/doi.org\/10.1080\/03610910801894870","journal-title":"Commun Stat Simul Comput"},{"issue":"13","key":"377_CR37","doi-asserted-by":"publisher","first-page":"811","DOI":"10.3109\/08958378.2014.955932","volume":"26","author":"LD Maxim","year":"2014","unstructured":"Maxim LD, Niebo R, Utell MJ (2014) Screening tests: a review with examples. Inhal Toxicol 26(13):811\u2013828. https:\/\/doi.org\/10.3109\/08958378.2014.955932","journal-title":"Inhal Toxicol"},{"issue":"10","key":"377_CR38","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.2337\/dc10-1303","volume":"33","author":"S Tesfaye","year":"2010","unstructured":"Tesfaye S, Boulton AJM, Dyck PJ et al (2010) Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 33(10):2285\u20132293. https:\/\/doi.org\/10.2337\/dc10-1303","journal-title":"Diabetes Care"},{"issue":"6","key":"377_CR39","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.pain.2012.03.003","volume":"153","author":"RH Dworkin","year":"2012","unstructured":"Dworkin RH, Turk DC, Peirce-Sandner S et al (2012) Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations. Pain 153(6):1148\u20131158","journal-title":"Pain"},{"issue":"2","key":"377_CR40","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jcm.2016.02.012","volume":"15","author":"TK Koo","year":"2016","unstructured":"Koo TK, Li MY (2016) A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med 15(2):155\u2013163. https:\/\/doi.org\/10.1016\/j.jcm.2016.02.012","journal-title":"J Chiropr Med"},{"issue":"1","key":"377_CR41","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jclinepi.2006.03.012","volume":"60","author":"CB Terwee","year":"2007","unstructured":"Terwee CB, Bot SDM, de Boer MR et al (2007) Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol 60(1):34\u201342. https:\/\/doi.org\/10.1016\/j.jclinepi.2006.03.012","journal-title":"J Clin Epidemiol"},{"key":"377_CR42","doi-asserted-by":"publisher","DOI":"10.1111\/jns.12335","author":"NP Staff","year":"2019","unstructured":"Staff NP, Cavaletti G, Islam B, Lustberg M, Psimaras D, Tamburin S (2019) Platinum-induced peripheral neurotoxicity: from pathogenesis to treatment. J Peripher Nerv Syst. https:\/\/doi.org\/10.1111\/jns.12335","journal-title":"J Peripher Nerv Syst"},{"key":"377_CR43","doi-asserted-by":"publisher","DOI":"10.1111\/jns.12338","author":"R Velasco","year":"2019","unstructured":"Velasco R, Alberti P, Bruna J, Psimaras D, Argyriou AA (2019) Bortezomib and other proteosome inhibitors-induced peripheral neurotoxicity: from pathogenesis to treatment. J Peripher Nerv Syst. https:\/\/doi.org\/10.1111\/jns.12338","journal-title":"J Peripher Nerv Syst"},{"issue":"3","key":"377_CR44","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1097\/j.pain.0000000000000404","volume":"157","author":"L Ventzel","year":"2016","unstructured":"Ventzel L, Jensen AB, Jensen AR, Jensen TS, Finnerup NB (2016) Chemotherapy-induced pain and neuropathy: a prospective study in patients treated with adjuvant oxaliplatin or docetaxel. Pain 157(3):560\u2013568. https:\/\/doi.org\/10.1097\/j.pain.0000000000000404","journal-title":"Pain"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-021-00377-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-021-00377-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-021-00377-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,26]],"date-time":"2021-09-26T21:11:48Z","timestamp":1632690708000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpro.springeropen.com\/articles\/10.1186\/s41687-021-00377-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,26]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["377"],"URL":"https:\/\/doi.org\/10.1186\/s41687-021-00377-z","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,26]]},"assertion":[{"value":"5 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Study oversight and ethics approval was provided by the Dana-Farber\/Harvard Cancer Center Office for Human Research Studies (18-049). All study participants provided written consent to participate in the trial.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RK has received personal fees (consulting) from Strategy Inc, Spark Healthcare, and System Analytic; and serves on the scientific advisory board of Wellium.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"101"}}